Signal Genetics Plans to Release Pharmacogenomic Version of Myeloma Test Later This Year

The company plans two new versions of its MyPRS test later this year, including a pharmacogenomic enhancement called MyPRS RX and a version called MyPRS Plus that will perform myeloma subgroup analysis.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.